Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jun 1;2017(2):2141-2148. doi: 10.1200/JCO.2016.70.8297.2017.2.test.

PMID:
29629819
2.

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

Barroso-Sousa R, Exman P, Tolaney SM.

Future Oncol. 2018 Apr;14(10):937-945. doi: 10.2217/fon-2017-2500. Epub 2018 Mar 28.

PMID:
29589471
3.

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK.

Sci Transl Med. 2018 Mar 14;10(432). pii: eaag0945. doi: 10.1126/scitranslmed.aag0945.

PMID:
29540614
4.

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L.

Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3. Review.

PMID:
29313945
5.

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TR, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA.

J Clin Oncol. 2018 Feb 20;36(6):543-553. doi: 10.1200/JCO.2017.76.0033. Epub 2018 Jan 3.

6.

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M.

Nat Commun. 2017 Nov 6;8(1):1324. doi: 10.1038/s41467-017-00965-y.

7.

Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.

Freedman RA, Tolaney SM.

Breast Cancer Res Treat. 2018 Feb;167(3):607-614. doi: 10.1007/s10549-017-4560-6. Epub 2017 Nov 4. Review.

PMID:
29103175
8.

Randomized trial of a clinic-based weight loss intervention in cancer survivors.

Brown JC, Yung RL, Gobbie-Hurder A, Shockro L, O'Connor K, Campbell N, Kasper J, Mayer EL, Tolaney SM, Partridge AH, Ligibel JA.

J Cancer Surviv. 2018 Apr;12(2):186-195. doi: 10.1007/s11764-017-0657-5. Epub 2017 Nov 3.

PMID:
29101711
9.

Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib.

Shinagare AB, Somarouthu B, Guo H, Tolaney SM, Ramaiya NH.

Clin Imaging. 2018 Mar - Apr;48:44-47. doi: 10.1016/j.clinimag.2017.09.014. Epub 2017 Sep 28.

PMID:
29028513
10.

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM.

JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.

PMID:
28973656
11.

Optimal Management of Early and Advanced HER2 Breast Cancer.

Hurvitz SA, Gelmon KA, Tolaney SM.

Am Soc Clin Oncol Educ Book. 2017;37:76-92. doi: 10.14694/EDBK_175630. Review.

12.

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J.

Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.

PMID:
28533223
13.

Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.

Mamiya H, Tahara RK, Tolaney SM, Choudhry NK, Najafzadeh M.

Ann Oncol. 2017 Aug 1;28(8):1825-1831. doi: 10.1093/annonc/mdx201.

PMID:
28472324
14.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

PMID:
28291390
15.

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL.

Clin Cancer Res. 2017 Jul 15;23(14):3520-3528. doi: 10.1158/1078-0432.CCR-16-1764. Epub 2016 Dec 28.

PMID:
28031425
16.

Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.

Irwin ML, Cartmel B, Harrigan M, Li F, Sanft T, Shockro L, O'Connor K, Campbell N, Tolaney SM, Mayer EL, Yung R, Freedman RA, Partridge AH, Ligibel JA.

Cancer. 2017 Apr 1;123(7):1249-1258. doi: 10.1002/cncr.30456. Epub 2016 Nov 28.

17.

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM.

Invest New Drugs. 2017 Feb;35(1):68-78. doi: 10.1007/s10637-016-0399-7. Epub 2016 Nov 16.

PMID:
27853996
18.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG.

Oncologist. 2017 Jan;22(1):25-32. doi: 10.1634/theoncologist.2016-0229. Epub 2016 Oct 27.

19.

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP.

Breast Cancer Res Treat. 2016 Nov;160(2):305-312. Epub 2016 Oct 6.

20.

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Barroso-Sousa R, Shapiro GI, Tolaney SM.

Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Epub 2016 Jun 22. Review.

21.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

22.

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ.

Cancer Cell. 2016 Mar 14;29(3):255-69. doi: 10.1016/j.ccell.2016.02.006.

23.

Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP.

Cancer. 2016 Apr 15;122(8):1169-77. doi: 10.1002/cncr.29899. Epub 2016 Feb 12.

24.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

25.

The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.

Waks AG, Tolaney SM.

Future Oncol. 2015;11(24):3261-71. doi: 10.2217/fon.15.240. Epub 2015 Nov 13. Review.

PMID:
26634944
26.

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2.

27.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.

JAMA Oncol. 2016 Jan;2(1):29-36. doi: 10.1001/jamaoncol.2015.3709.

28.

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

Blackwell K, Burris H, Gomez P, Lynn Henry N, Isakoff S, Campana F, Gao L, Jiang J, Macé S, Tolaney SM.

Breast Cancer Res Treat. 2015 Nov;154(2):287-97. doi: 10.1007/s10549-015-3615-9. Epub 2015 Oct 24.

PMID:
26497877
29.

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.

Waks AG, Tolaney SM, Galar A, Arnaout A, Porter JB, Marty FM, Winer EP, Hammond SP, Baden LR.

Breast Cancer Res Treat. 2015 Nov;154(2):359-67. doi: 10.1007/s10549-015-3573-2. Epub 2015 Sep 29.

PMID:
26420402
30.

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.

Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE.

Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.

31.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

32.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. Erratum in: N Engl J Med. 2015 Nov 12;373(20):1989.

34.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP.

J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.

35.

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.

Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE.

Cancer Med. 2014 Apr;3(2):293-9. doi: 10.1002/cam4.164. Epub 2014 Jan 27.

36.

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.

J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.

PMID:
24323026
37.

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.

Breast Cancer Res Treat. 2013 Oct;141(3):421-7. doi: 10.1007/s10549-013-2700-1. Epub 2013 Sep 24.

PMID:
24062210
38.

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.

Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M.

Breast Cancer Res Treat. 2013 Sep;141(2):255-9. doi: 10.1007/s10549-013-2682-z. Epub 2013 Sep 13.

PMID:
24026859
39.

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.

Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.

40.

A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.

Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, Fornier M, Winer EP, Bunnell C, Krop IE.

Ann Oncol. 2013 Jul;24(7):1841-7. doi: 10.1093/annonc/mdt121. Epub 2013 Apr 4.

41.

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N; Cancer and Leukemia Group B.

J Natl Cancer Inst. 2010 Jul 7;102(13):942-9. doi: 10.1093/jnci/djq211. Epub 2010 Jun 16. Erratum in: J Natl Cancer Inst. 2010 Aug 4;102(15):1210. Paskett, Electra M [corrected to Paskett, Electra D].

42.

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE.

Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. Review.

PMID:
19275526
43.

Lymphopenia associated with adjuvant anthracycline/ taxane regimens.

Tolaney SM, Najita J, Winer EP, Burstein HJ.

Clin Breast Cancer. 2008 Aug;8(4):352-6. doi: 10.3816/CBC.2008.n.041.

PMID:
18757263
44.

Sarcoidosis mimicking metastatic breast cancer.

Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP.

Clin Breast Cancer. 2007 Oct;7(10):804-10.

PMID:
18021484
45.

Follow-up care of patients with breast cancer.

Tolaney SM, Winer EP.

Breast. 2007 Dec;16 Suppl 2:S45-50. Epub 2007 Aug 13. Review.

PMID:
17697780
46.

Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.

Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP.

J Clin Oncol. 2006 Nov 20;24(33):5330-1. No abstract available.

PMID:
17114668

Supplemental Content

Loading ...
Support Center